# TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

> **NCT04475016** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 29 (actual)

## Conditions studied

- Penile Cancer

## Interventions

- **DRUG:** Albumin-Bound Paclitaxel
- **DRUG:** Ifosfamide
- **DRUG:** Cisplatin
- **DRUG:** Nimotuzumab
- **DRUG:** Triprilimab

## Key facts

- **NCT ID:** NCT04475016
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-12
- **Primary completion:** 2022-05-06
- **Final completion:** 2022-05-30
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2022-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04475016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04475016, "TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT04475016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*